替罗非班治疗缺血性卒中的研究进展

Research progress of Tirofiban in treatment of ischemic stroke

缺血性卒中是我国首位致死病因,抗血小板是基础治疗,但常用的抗血小板药物如阿司匹林、氯吡格雷并未完全覆盖所有血小板聚集的信号通路。糖蛋白(GP)Ⅱb/Ⅲa拮抗剂替罗非班作为一种新的抗血小板药物,起效快,半衰期短,具有可逆性,通过阻断血小板聚集的共同途径发挥作用。替罗非班在心血管疾病中应用成熟,但在脑血管领域仍属于探索阶段,属于超说明书用药。本文对目前的关于替罗非班治疗脑卒中的研究进行综述。

Ischaemic stroke is the leading cause of death in China,and antiplatelet therapy serves as a fundamental treatment.However,typical antiplatelet drugs such as aspirin and clopidogrel fail to entirely inhibit all the platelet aggregation signaling pathways.Tirofiban,a novel antiplatelet medicine that acts as a glycoprotein(GP)IIb/IIIa antagonist,rapidly intervenes,has a short half-life,and can be reversed.Its mechanism of action is achieved through the blockage of the common pathway of platelet aggregation.Tirofiban has a well-established role in treating cardiovascular diseases,yet its use in the cerebrovascular field is still experimental.It is off-label drug use.This article reviews current research on the efficacy of tirofiban in treating stroke.